ASSAY THEORY ___________________________________________________________ 2

ADAPTA ASSAY CONDITIONS __________________________________________________ 3

ADAPTA ASSAY CONTROLS _____________________________________________________ 4

ADAPTA DATA ANALYSIS _____________________________________________________ 5

KINASE-SPECIFIC ASSAY CONDITIONS ___________________________________________ 6

CAMK1 (CaMK1) Error! Bookmark not defined.
CDK4/cyclin D1 Error! Bookmark not defined.
CDK6/cyclin D1 Error! Bookmark not defined.
CDK7/cyclin HMMAT1 Error! Bookmark not defined.
CDK9/cyclin T1 Error! Bookmark not defined.
CHEK (IKK alpha) Error! Bookmark not defined.
DAPK1 Error! Bookmark not defined.
GSK2 (Glycogen synthase kinase 2) Error! Bookmark not defined.
IRAK1 Error! Bookmark not defined.
LRRK2 Error! Bookmark not defined.
LRRK2 G2019S Error! Bookmark not defined.
LRRK2 G2019S FL Error! Bookmark not defined.
LRRK2 G2020T Error! Bookmark not defined.
LRRK2 R1441C Error! Bookmark not defined.
NUAK1 (ARK5) Error! Bookmark not defined.
PHK2A (PIPK2 alpha) Error! Bookmark not defined.
PHK2B (PIPK2 beta) Error! Bookmark not defined.
PHK4 (PIPK4 alpha) Error! Bookmark not defined.
PHKB (PIPK5 beta) Error! Bookmark not defined.
PKC2A (PKC2-C2 alpha) Error! Bookmark not defined.
PKC2B (PKC2-C2 beta) Error! Bookmark not defined.
PKC2G (PKC2-C2 gamma) Error! Bookmark not defined.
PKC3 (hPK3) Error! Bookmark not defined.
PKC3A E542K-PKC3R1 (p110 alpha E542K/p85 alpha) Error! Bookmark not defined.
PKC3A E542K-PKC3R1 (p110 alpha E542K/p85 alpha) Error! Bookmark not defined.
PKC3A-PKC3R1 (p110 alpha/p85 alpha) Error! Bookmark not defined.
PKC3A-PKC3R3 (p110 alpha/p85 gamma) Error! Bookmark not defined.
PKC3B-PKC3R1 (p110 beta/p85 alpha) Error! Bookmark not defined.
PKC3B-PKC3R2 (p110 beta/p85 beta) Error! Bookmark not defined.
PKC3C-PKC3R1 (p110 delta/p85 alpha) Error! Bookmark not defined.
PKC3C (p110 gamma) Error! Bookmark not defined.

PIPK4A Error! Bookmark not defined.
PIPK5A Error! Bookmark not defined.
PIPK5B Error! Bookmark not defined.
PIPK5C Error! Bookmark not defined.
SPHK1 Error! Bookmark not defined.
SPHK2 Error! Bookmark not defined.

TABLE OF KINASE ATP KM BINS AND INHIBITOR VALIDATION ___________________________________________ 10

Thermo Fisher Scientific • www.thermofisher.com/selectscreen
Assay Theory

The Adapta universal kinase assay is a homogenous, fluorescent based immunoassay for the detection of ADP. In contrast to ATP depletion assays, the Adapta assay is extremely sensitive to ADP formation such that a majority of the signal change occurs in the first 10-20% conversion of ATP to ADP. This makes the Adapta universal kinase assay ideally suited for use with low activity kinases.

The principle of the Adapta universal kinase assay is outlined below. The assay itself can be divided into two phases: a kinase reaction phase, and an ADP detection phase. In the kinase reaction phase, all components required for the kinase reaction are added to the well, and the reaction is allowed to incubate for 60 minutes. After the reaction, a detection solution consisting of a europium labeled anti-ADP antibody, an Alexa Fluor™ 647 labeled ADP tracer, and EDTA (to stop the kinase reaction) is added to the assay well. ADP formed by the kinase reaction (in the absence of an inhibitor) will displace the Alexa Fluor 647 labeled ADP tracer from the antibody, resulting in a decrease in the TR-FRET signal. In the presence of an inhibitor, the amount of ADP formed by the kinase reaction is reduced, and the resulting intact antibody-tracer interaction results in a high TR-FRET signal.

ADP formation is determined by calculating the emission ratio from the assay well. The emission ratio is calculated by dividing the intensity of the tracer (acceptor) emission by the intensity of the Eu (donor) emission at 615 nm as shown in the equation below.

\[
\text{Emission Ratio} = \frac{\text{AlexaFluor647 Emission (665 nm)}}{\text{Europium Emission (615 nm)}}
\]
Since the Adapta technology measures ADP formation (i.e. conversion of ATP to ADP) it can be used to measure any type of ATP hydrolysis, including intrinsic ATPase activity of kinases. In this case, the substrate is water, not a lipid or peptide. The SelectScreen service screens CHUK in this way, so a substrate is not included in the kinase reaction. A reference for using intrinsic ATPase activity to screen for kinase inhibitors is provided below.


**Adapta Assay Conditions**

**Test Compounds**
The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold serial dilutions are conducted from the starting concentration of the customer’s choosing.

**Substrate/Kinase Mixtures**
All Substrate/Kinase Mixtures are diluted to a 2X working concentration in the appropriate Kinase Buffer (see section *Kinase Specific Assay Conditions* for a complete description).

**ATP Solution**
All ATP Solutions are diluted to a 4X working concentration in water.

ATP Km apparent is previously determined using a radiometric assay except when no substrate is available in which case an Adapta assay is conducted.

**Detection Mix**
The Detection Mix is prepared in TR-FRET Dilution Buffer. The Detection mix consists of EDTA (30 mM), Eu-anti-ADP antibody (6 nM) and ADP tracer. The detection mix contains the EC$_{60}$ concentration of tracer for 5-150 µM ATP.

**Assay Protocol**
*Bar-coded Corning, low volume, white 384-well plate (Corning Cat. #4512)*
1. 100 nL – 100X Test Compound in 100% DMSO
2. 2.4 µL – 30 mM HEPES
3. 2.5 µL – 4X ATP Solution
4. 5 µL – 2X Substrate/Kinase Mixture
5. 30-second plate shake
6. 1-minute centrifuge at 1000 x g
7. 60-minute Kinase Reaction incubation at room temperature
8. 5 µL – Detection Mix
9. 30-second plate shake
10. 1-minute centrifuge at 1000 x g
11. 60-minute Detection Mix equilibration at room temperature
12. Read on fluorescence plate reader and analyze the data
Adapta Assay Controls

The following controls are made for each individual kinase and are located on the same plate as the kinase:

0% Conversion Control (100% Inhibition Control)
The maximum Emission Ratio is established by the 0% Conversion Control (100% Inhibition Control), which contains no ATP in the kinase reaction and therefore exhibits no kinase activity. After addition of the Detection Mix containing EDTA, ATP is added to these wells. ATP addition is required for the 0% conversion controls wells because the ADP antibody binds ATP with low affinity. The ATP in wells with maximum kinase inhibition will displace the ADP tracer slightly, though much less efficiently than ADP.

100% Conversion Control
The 100% Conversion Control wells contain ADP instead of ATP and are designed to allow for the calculation of percent ATP conversion.

The 0% Conversion and 100% Conversion Controls allow one to estimate the percent ATP Conversion achieved in a specific reaction well. Control wells do not include any kinase inhibitors.

0% Inhibition Control
The minimum Emission Ratio in a screen is established by the 0% Inhibition Control, which contains active kinase. This control is designed to produce < 40%* ATP conversion in the Kinase Reaction.

*The range of ATP conversion allowed is different for each kinase and set in the linear region.

Known Inhibitor
A known inhibitor control standard curve, 10 point titration, is run for each individual kinase on the same plate as the kinase to ensure the kinase is inhibited within an expected IC_{50} range previously determined.
Adapta Data Analysis

The following equations are used for each set of data points:

We run Adapta assays in the linear range determined for each kinase. Full ATP/ADP standard curves are run during validation to define this range. In addition, ATP/ADP standard curves are used to calculate the percent ATP conversion of each sample.

<table>
<thead>
<tr>
<th>Equation</th>
</tr>
</thead>
</table>
| **Emission Ratio** | \[
\frac{\text{AF647 Emission (665 nm)}}{\text{Europium Emission (615 nm)}}
\] |
| **% Conversion** | \[
\left\{ \frac{\text{EC}_{50 \text{ SC}}}{\left( \frac{\text{Top SC} - \text{Bottom SC}}{\text{Emission Ratio}_{\text{Sample}} - \text{Bottom SC}} \right) - 1 \left( \frac{1}{\text{Hillslope}_{\text{SC}}} \right)} \right\} \times 100
\] |
| **% Inhibition** | \[
\left\{ \frac{1 - \frac{\text{Conversion}_{\text{Sample}}}{\text{Conversion}_{0\% \text{ Inhibition Ctrl}}}}{\text{Conversion}_{0\% \text{ Inhibition Ctrl}}} \right\} \times 100
\] |
| **Difference Between Data Points** | \[
\left| \text{\% Inhibition}_{\text{Point 1}} - \text{\% Inhibition}_{\text{Point 2}} \right|
\] |
| **Test Compound Interference** | For each emission wavelength, fluorescence interference is flagged for a compound well that is more than 20% outside the range of the controls. |
| **Z'** | \[
1 - \frac{3 \times \text{Stdev}_{0\% \text{ Conv Ctrl}} + 3 \times \text{Stdev}_{0\% \text{ Inhibition}}}{\left| \text{Mean}_{0\% \text{ Conv Ctrl}} \times \text{Mean}_{0\% \text{ Inhibition}} \right|}
\] |

* SC = Standard Curve

Graphing Software

SelectScreen Kinase Profiling Service uses XLfit from IDBS. The ATP/ADP standard curve is fit to model number 205 (sigmoidal dose-response model). The dose response curve is also curve fit to model number 205. If the bottom of the curve does not fit between -20% & 20% inhibition, it is set to 0% inhibition. If the top of the curve does not fit between 70% and 130% inhibition, it is set to 100% inhibition.
Kinase-Specific Assay Conditions

Note about Lipid Substrates

Lipid substrates are prepared by creating lipid vesicles. In some cases, these vesicles include a carrier lipid, such as phosphatidylserine (PS). In the assay conditions section below, “PIP2:PS” refers to large unilamellar vesicles (LUVs) containing five mole percent L-α-Phosphatidylinositol-4,5-bisphosphate and ninety-five percent phosphatidylserine. The concentration listed refers only to the PIP2 substrate, not the PS carrier lipid.

CAMK1 (CaMK1)
The 2X CAMK1 (CaMK1) / ZIPtide mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 800 U/ml Calmodulin, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 1.58 - 12 ng CAMK1 (CaMK1) and 200 µM ZIPtide in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MgCl2, 500 µM EGTA, 2 mM CaCl2, 400 U/ml Calmodulin, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

CDK4/cyclin D1
The 2X CDK4/cyclin D1 / Rb Substrate mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 7.5 - 30 ng CDK4/cyclin D1 and 1 µM Rb Substrate in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MnCl2, 0.5 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

CDK4/cyclin D3
The 2X CDK4/cyclin D3 / Rb Substrate mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 12.5 - 50 ng CDK4/cyclin D3 and 1 µM Rb Substrate in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MnCl2, 0.3 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

CDK6/cyclin D1
The 2X CDK6/cyclin D1 / Rb Substrate mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 1.75 - 7 ng CDK6/cyclin D1 and 1 µM Rb Substrate in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MnCl2, 0.5 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

CDK7/cyclin H/MNAT1
The 2X CDK7/cyclin H/MNAT1 / CDK7/9tide mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 2.87 - 38.75 ng CDK7/cyclin H/MNAT1 and 200 µM CDK7/9tide in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MgCl2, 0.5 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

CDK9/cyclin T1
The 2X CDK9/cyclin T1 / CDK7/9tide mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 4 - 40 ng CDK9/cyclin T1 and 200 µM CDK7/9tide in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MgCl2, 0.5 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

CHUK (IKK alpha)
The 2X CHUK (IKK alpha) is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 15 - 120 ng CHUK (IKK alpha) in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MgCl2, 0.5 mM EGTA. No substrate is required, as this assay measures the ability of a compound to inhibit the kinase's intrinsic ATPase activity. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

DAPK1
The 2X DAPK1 / ZIPtide mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 800 U/ml Calmodulin, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 0.22 - 5.4 ng DAPK1 and 200 µM ZIPtide in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MgCl2, 500 µM EGTA, 2 mM CaCl2, 400 U/ml Calmodulin, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.
**GS2 (Haspin)**
The 2X GS2 (Haspin) / Histone H3 (1-20) peptide mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.1 - 1.4 ng GS2 (Haspin) and 100 µM Histone H3 (1-20) peptide in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MgCl2, 0.5 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

**IRAK1**
The 2X IRAK1 / Histone H3 (1-20) peptide mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 3.17 - 30.5 ng IRAK1 and 100 µM Histone H3 (1-20) peptide in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MgCl2, 0.5 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

**LRRK2**
The 2X LRRK2 / ERM (LRRKtide) mixture is prepared in 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 3.75 - 70 ng LRRK2 and 200 µM ERM (LRRKtide) in 25 mM Tris / 7.5 mM HEPES pH 8.2, 0.005% BRIJ-35, 5 mM MgCl2, 0.5 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

**LRRK2 FL**
The 2X LRRK2 FL / ERM (LRRKtide) mixture is prepared in 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 5 - 70 ng LRRK2 FL and 200 µM ERM (LRRKtide) in 25 mM Tris / 7.5 mM HEPES pH 8.2, 0.005% BRIJ-35, 5 mM MgCl2, 0.5 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

**LRRK2 G2019S**
The 2X LRRK2 G2019S / ERM (LRRKtide) mixture is prepared in 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 3 - 12 ng LRRK2 G2019S and 200 µM ERM (LRRKtide) in 25 mM Tris / 7.5 mM HEPES pH 8.2, 0.005% BRIJ-35, 5 mM MgCl2, 0.5 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

**LRRK2 G2019S FL**
The 2X LRRK2 G2019S FL / ERM (LRRKtide) mixture is prepared in 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 2.5 - 30 ng LRRK2 G2019S FL and 200 µM ERM (LRRKtide) in 25 mM Tris / 7.5 mM HEPES pH 8.2, 0.005% BRIJ-35, 5 mM MgCl2, 0.5 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

**LRRK2 I2020T**
The 2X LRRK2 I2020T / ERM (LRRKtide) mixture is prepared in 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 4 - 110 ng LRRK2 I2020T and 200 µM ERM (LRRKtide) in 25 mM Tris / 7.5 mM HEPES pH 8.2, 0.005% BRIJ-35, 5 mM MgCl2, 0.5 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

**LRRK2 R1441C**
The 2X LRRK2 R1441C / ERM (LRRKtide) mixture is prepared in 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 7.5 - 60 ng LRRK2 R1441C and 200 µM ERM (LRRKtide) in 25 mM Tris / 7.5 mM HEPES pH 8.2, 0.005% BRIJ-35, 5 mM MgCl2, 0.5 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

**NUA1 (ARK5)**
The 2X NUAK1 (ARK5) / CHKtide mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 2.5 - 30 ng NUAK1 (ARK5) and 200 µM CHKtide in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MgCl2, 0.5 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

**PI4K2A (PI4K2 alpha)**
The 2X PI4K2A (PI4K2 alpha) / PI Lipid Kinase Substrate mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 7.5 - 40 ng PI4K2A (PI4K2 alpha) and 100 µM PI Lipid Kinase Substrate in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MnCl2, 0.5 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

**PI4K2B (PI4K2 beta)**
The 2X PI4K2B (PI4K2 beta) / PI Lipid Kinase Substrate mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 3.75 - 20 ng PI4K2B (PI4K2 beta) and 100 µM PI Lipid Kinase Substrate in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MnCl2, 0.5 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.
PI4KA (PI4K alpha)
The 2X PI4KA (PI4K alpha) / PI Lipid Kinase Substrate mixture is prepared in 20 mM Tris, pH 7.5, 0.4% Triton X-100, 5 mM MgCl₂, 0.5 mM EGTA. The final 10 µL Kinase Reaction consists of 75 - 300 ng PI4KA (PI4K alpha) and 100 µM PI Lipid Kinase Substrate in 7.5 mM HEPES, 10 mM Tris, pH 7.5, 0.2% Triton X-100, 2.5 mM MgCl₂, 0.25 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

PI4KB (PI4K beta)
The 2X PI4KB (PI4K beta) / PI Lipid Kinase Substrate mixture is prepared in 50 mM HEPES pH 7.5, 0.1% CHAPS, 1 mM EGTA, 4 mM MgCl₂. The final 10 µL Kinase Reaction consists of 3.75 - 60 ng PI4KB (PI4K beta) and 100 µM PI Lipid Kinase Substrate in 32.5 mM HEPES pH 7.5, 0.05% CHAPS, 0.5 mM EGTA, 2 mM MgCl₂. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

PIK3C2A (PI3K-C2 alpha)
The 2X PIK3C2A (PI3K-C2 alpha) / PI Lipid Kinase Substrate mixture is prepared in 100 mM HEPES pH 7.5, 200 mM NaCl, 0.06% CHAPS, 2 mM EGTA, 6 mM MgCl₂, 4 mM DTT. The final 10 µL Kinase Reaction consists of 10 - 120 ng PIK3C2A (PI3K-C2 alpha) and 100 µM PI Lipid Kinase Substrate in 57.5 mM HEPES pH 7.5, 100 mM NaCl, 0.03% CHAPS, 1 mM EGTA, 3 mM MgCl₂, 2 mM DTT. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

PIK3C2B (PI3K-C2 beta)
The 2X PIK3C2B (PI3K-C2 beta) / PI Lipid Kinase Substrate mixture is prepared in 100 mM HEPES pH 7.5, 200 mM NaCl, 0.06% CHAPS, 2 mM EGTA, 6 mM MgCl₂, 4 mM DTT. The final 10 µL Kinase Reaction consists of 50 - 250 ng PIK3C2B (PI3K-C2 beta) and 100 µM PI Lipid Kinase Substrate in 57.5 mM HEPES pH 7.5, 100 mM NaCl, 0.03% CHAPS, 1 mM EGTA, 3 mM MgCl₂, 2 mM DTT. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

PIK3C2G (PI3K-C2 gamma)
The 2X PIK3C2G (PI3K-C2 gamma) / PI Lipid Kinase Substrate mixture is prepared in 100 mM HEPES pH 7.5, 200 mM NaCl, 0.06% CHAPS, 2 mM EGTA, 6 mM MgCl₂, 4 mM DTT. The final 10 µL Kinase Reaction consists of 1 - 28 ng PIK3C2G (PI3K-C2 gamma) and 100 µM PI Lipid Kinase Substrate in 57.5 mM HEPES pH 7.5, 100 mM NaCl, 0.03% CHAPS, 1 mM EGTA, 3 mM MgCl₂, 2 mM DTT. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

PIK3C3 (hVPS34)
The 2X PIK3C3 (hVPS34) / PI Lipid Kinase Substrate mixture is prepared in 100 mM HEPES pH 7.5, 0.2% CHAPS, 10 mM MnCl₂, 2 mM EGTA. The final 10 µL Kinase Reaction consists of 2 - 38.65 ng PIK3C3 (hVPS34) and 100 µM PI Lipid Kinase Substrate in 57.5 mM HEPES pH 7.5, 0.1% CHAPS, 5 mM MnCl₂, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

PIK3CA E542K/PIK3R1 (p110 alpha E542K/p85 alpha)
The 2X PIK3CA E542K/PIK3R1 (p110 alpha E542K/p85 alpha) / PIP2:PS mixture is prepared in 100 mM HEPES pH 7.5, 200 mM NaCl, 0.06% CHAPS, 2 mM EGTA, 6 mM MgCl₂, 4 mM DTT. The final 10 µL Kinase Reaction consists of 15 - 60 ng PIK3CA E542K/PIK3R1 (p110 alpha E542K/p85 alpha) and 50 µM PIP2:PS in 57.5 mM HEPES pH 7.5, 100 mM NaCl, 0.03% CHAPS, 1 mM EGTA, 3 mM MgCl₂, 2 mM DTT. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

PIK3CA E545K/PIK3R1 (p110 alpha E545K/p85 alpha)
The 2X PIK3CA E545K/PIK3R1 (p110 alpha E545K/p85 alpha) / PIP2:PS mixture is prepared in 50 mM HEPES pH 7.5, 100 mM NaCl, 0.03% CHAPS, 3 mM MgCl₂, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 1 - 8 ng PIK3CA E545K/PIK3R1 (p110 alpha E545K/p85 alpha) and 50 µM PIP2:PS in 32.5 mM HEPES pH 7.5, 50 mM NaCl, 0.015% CHAPS, 1.5 mM MgCl₂, 0.5 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

PIK3CA/PIK3R3 (p110 alpha/p55 gamma)
The 2X PIK3CA/PIK3R3 (p110 alpha/p55 gamma) / PIP2:PS mixture is prepared in 50 mM HEPES pH 7.5, 100 mM NaCl, 0.03% CHAPS, 3 mM MgCl₂, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 1.25 - 12 ng PIK3CA/PIK3R3 (p110 alpha/p55 gamma) and 50 µM PIP2:PS in 32.5 mM HEPES pH 7.5, 50 mM NaCl, 0.015% CHAPS, 1.5 mM MgCl₂, 0.5 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.
PIK3CB/PIK3R1 (p110 beta/p85 alpha)
The 2X PIK3CB/PIK3R1 (p110 beta/p85 alpha) / PIP2:PS mixture is prepared in 50 mM HEPES pH 7.5, 100 mM NaCl, 0.03% CHAPS, 3 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 6.25 - 80 ng PIK3CB/PIK3R1 (p110 beta/p85 alpha) and 50 µM PIP2:PS in 32.5 mM HEPES pH 7.5, 50 mM NaCl, 0.015% CHAPS, 1.5 mM MgCl2, 0.5 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

PIK3CB/PIK3R2 (p110 beta/p85 beta)
The 2X PIK3CB/PIK3R2 (p110 beta/p85 beta) / PIP2:PS mixture is prepared in 50 mM HEPES pH 7.5, 100 mM NaCl, 0.03% CHAPS, 3 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 4.5 - 60 ng PIK3CB/PIK3R2 (p110 beta/p85 beta) and 50 µM PIP2:PS in 32.5 mM HEPES pH 7.5, 50 mM NaCl, 0.015% CHAPS, 1.5 mM MgCl2, 0.5 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

PIK3CD/PIK3R1 (p110 delta/p85 alpha)
The 2X PIK3CD/PIK3R1 (p110 delta/p85 alpha) / PIP2:PS mixture is prepared in 50 mM HEPES pH 7.5, 100 mM NaCl, 0.03% CHAPS, 3 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.3 - 3 ng PIK3CD/PIK3R1 (p110 delta/p85 alpha) and 50 µM PIP2:PS in 32.5 mM HEPES pH 7.5, 50 mM NaCl, 0.015% CHAPS, 1.5 mM MgCl2, 0.5 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

PIK3CG (p110 gamma)
The 2X PIK3CG (p110 gamma) / PIP2:PS mixture is prepared in 50 mM HEPES pH 7.5, 1 mM EGTA, 3 mM MgCl2. The final 10 µL Kinase Reaction consists of 6.25 - 40 ng PIK3CG (p110 gamma) and 50 µM PIP2:PS in 32.5 mM HEPES pH 7.5, 0.5 mM EGTA, 1.5 mM MgCl2. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

PI4P2A
The 2X PI4P2A / PI(5)P mixture is prepared in 50 mM HEPES pH 7.5, 0.1% CHAPS, 1 mM EGTA, 4 mM MgCl2. The final 10 µL Kinase Reaction consists of 1.5 - 6 ng PI4P2A and 50 µM PI(5)P in 32.5 mM HEPES pH 7.5, 0.05% CHAPS, 0.5 mM EGTA, 2 mM MgCl2. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

PI5K1A
The 2X PI5K1A / PI(3;4)P2 mixture is prepared in 100 mM HEPES pH 7.5, 200 mM NaCl, 0.06% CHAPS, 2 mM EGTA, 6 mM MgCl2, 4 mM DTT. The final 10 µL Kinase Reaction consists of 2.5 - 10 ng PI5K1A and 50 µM PI(3;4)P2 in 57.5 mM HEPES pH 7.5, 100 mM NaCl, 0.03% CHAPS, 1 mM EGTA, 3 mM MgCl2, 2 mM DTT. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

PI5K1B
The 2X PI5K1B / PI(3;4)P2 mixture is prepared in 100 mM HEPES pH 7.5, 200 mM NaCl, 0.06% CHAPS, 2 mM EGTA, 6 mM MgCl2, 4 mM DTT. The final 10 µL Kinase Reaction consists of 15 - 60 ng PI5K1B and 50 µM PI(3;4)P2 in 57.5 mM HEPES pH 7.5, 100 mM NaCl, 0.03% CHAPS, 1 mM EGTA, 3 mM MgCl2, 2 mM DTT. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

PI5K1C
The 2X PI5K1C / PI(3;4)P2 mixture is prepared in 100 mM HEPES pH 7.5, 200 mM NaCl, 0.06% CHAPS, 2 mM EGTA, 6 mM MgCl2, 4 mM DTT. The final 10 µL Kinase Reaction consists of 3 - 12 ng PI5K1C and 50 µM PI(3;4)P2 in 57.5 mM HEPES pH 7.5, 100 mM NaCl, 0.03% CHAPS, 1 mM EGTA, 3 mM MgCl2, 2 mM DTT. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

SPHK1
The 2X SPHK1 / Sphingosine Lipid Substrate mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.05 - 1.1 ng SPHK1 and 50 µM Sphingosine Lipid Substrate in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MgCl2, 0.5 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

SPHK2
The 2X SPHK2 / Sphingosine Lipid Substrate mixture is prepared in 50 mM HEPES pH 7.5, 1 mM EGTA, 3 mM MgCl2. The final 10 µL Kinase Reaction consists of 40 - 250 ng SPHK2 and 50 µM Sphingosine Lipid Substrate in 32.5 mM HEPES pH 7.5, 0.5 mM EGTA, 1.5 mM MgCl2. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.
### Table of Kinase ATP Km Bins and Inhibitor Validation

The table below provides specifications and data around each kinase. The representative IC50 value with a known inhibitor for each kinase was determined at the ATP bin nearest to the ATP Km app, unless indicated with an asterisk (*) in which case the IC50 value was determined at 10 µM ATP.

<table>
<thead>
<tr>
<th>Kinase</th>
<th>Substrate</th>
<th>ATP Km app (µM)</th>
<th>ATP Bin (µM)</th>
<th>Inhibitor</th>
<th>IC50 (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAMK1 (CaMK1)</td>
<td>ZIPtide</td>
<td>845</td>
<td>N/A</td>
<td>Staurosporine</td>
<td>3.61 *</td>
</tr>
<tr>
<td>CDK4/cyclin D1</td>
<td>Rb Substrate</td>
<td>1</td>
<td>N/A</td>
<td>Staurosporine</td>
<td>66.1 *</td>
</tr>
<tr>
<td>CDK4/cyclin D3</td>
<td>Rb Substrate</td>
<td>1</td>
<td>N/A</td>
<td>Staurosporine</td>
<td>68.7 *</td>
</tr>
<tr>
<td>CDK6/cyclin D1</td>
<td>Rb Substrate</td>
<td>1</td>
<td>N/A</td>
<td>Staurosporine</td>
<td>11.8 *</td>
</tr>
<tr>
<td>CDK7/cyclin H/MNAT1</td>
<td>CDK7/9tide</td>
<td>153</td>
<td>150</td>
<td>Staurosporine</td>
<td>36.9</td>
</tr>
<tr>
<td>CDK9/cyclin T1</td>
<td>CDK7/9tide</td>
<td>32</td>
<td>25</td>
<td>Staurosporine</td>
<td>4.52</td>
</tr>
<tr>
<td>CHUK (IKK alpha)</td>
<td>None</td>
<td>8.8</td>
<td>10</td>
<td>Staurosporine</td>
<td>36.6</td>
</tr>
<tr>
<td>DAPK1</td>
<td>ZIPtide</td>
<td>5.8</td>
<td>5</td>
<td>Staurosporine</td>
<td>2.34</td>
</tr>
<tr>
<td>GSG2 (Haspin)</td>
<td>Histone H3 (1-20)</td>
<td>32</td>
<td>25</td>
<td>Staurosporine</td>
<td>5.39</td>
</tr>
<tr>
<td>IRAK1</td>
<td>Histone H3 (1-20)</td>
<td>36.5</td>
<td>25</td>
<td>Staurosporine</td>
<td>21.1</td>
</tr>
<tr>
<td>LRRK2</td>
<td>ERM (LRRKtide)</td>
<td>70</td>
<td>75</td>
<td>Staurosporine</td>
<td>1.51</td>
</tr>
<tr>
<td>LRRK2 G2019S</td>
<td>ERM (LRRKtide)</td>
<td>100</td>
<td>100</td>
<td>Staurosporine</td>
<td>0.601</td>
</tr>
<tr>
<td>LRRK2 G2019S FL</td>
<td>ERM (LRRKtide)</td>
<td>134</td>
<td>150</td>
<td>Staurosporine</td>
<td>0.802</td>
</tr>
<tr>
<td>LRRK2 I2020T</td>
<td>ERM (LRRKtide)</td>
<td>7.5</td>
<td>10</td>
<td>Staurosporine</td>
<td>0.862</td>
</tr>
<tr>
<td>LRRK2 R1441C</td>
<td>ERM (LRRKtide)</td>
<td>60</td>
<td>50</td>
<td>Staurosporine</td>
<td>1.94</td>
</tr>
<tr>
<td>NUAK1 (ARK5)</td>
<td>CHKtide</td>
<td>35</td>
<td>25</td>
<td>Staurosporine</td>
<td>2.53</td>
</tr>
<tr>
<td>PI4K2A (PI4K alpha)</td>
<td>PI Lipid Kinase Substrate</td>
<td>2</td>
<td>5</td>
<td>Staurosporine</td>
<td>13900</td>
</tr>
<tr>
<td>PI4K2B (PI4K beta)</td>
<td>PI Lipid Kinase Substrate</td>
<td>4</td>
<td>5</td>
<td>None</td>
<td>---</td>
</tr>
<tr>
<td>PI4KA (PI4K alpha)</td>
<td>PI Lipid Kinase Substrate</td>
<td>132</td>
<td>N/A</td>
<td>None</td>
<td>--- *</td>
</tr>
<tr>
<td>PI4KB (PI4K beta)</td>
<td>PI Lipid Kinase Substrate</td>
<td>6.7</td>
<td>5</td>
<td>PIK-93</td>
<td>6.06</td>
</tr>
<tr>
<td>PIK3C2A (PI3K-C2 alpha)</td>
<td>PI Lipid Kinase Substrate</td>
<td>19</td>
<td>25</td>
<td>PI-103</td>
<td>129</td>
</tr>
<tr>
<td>PIK3C2B (PI3K-C2 beta)</td>
<td>PI Lipid Kinase Substrate</td>
<td>150</td>
<td>N/A</td>
<td>PI-103</td>
<td>4.30 *</td>
</tr>
<tr>
<td>PIK3C2G (PI3K-C2 gamma)</td>
<td>PI Lipid Kinase Substrate</td>
<td>128</td>
<td>150</td>
<td>PI-103</td>
<td>11.9</td>
</tr>
<tr>
<td>PIK3C3 (hVPS34)</td>
<td>PI Lipid Kinase Substrate</td>
<td>9.3</td>
<td>10</td>
<td>PIK-93</td>
<td>1190</td>
</tr>
<tr>
<td>PIK3CA E542K/PIK3R1 (p110alpha E542K/p85 alpha)</td>
<td>PIP2:PS</td>
<td>1</td>
<td>N/A</td>
<td>PI-103</td>
<td>3.36 *</td>
</tr>
<tr>
<td>PIK3CA E545K/PIK3R1 (p110alpha E545K/p85 alpha)</td>
<td>PIP2:PS</td>
<td>98</td>
<td>100</td>
<td>PI-103</td>
<td>6.15</td>
</tr>
<tr>
<td>PIK3CA/PIK3R1 (p110)</td>
<td>PIP2:PS</td>
<td>25</td>
<td>25</td>
<td>PI-103</td>
<td>4.14</td>
</tr>
<tr>
<td>Kinase Complex</td>
<td>Substrate</td>
<td>PI-103</td>
<td>Staurosporine</td>
<td>JAK3 Inhibitor V</td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>-----------</td>
<td>--------</td>
<td>---------------</td>
<td>-----------------</td>
<td></td>
</tr>
<tr>
<td>alpha/p85 alpha</td>
<td>PIP2:PS</td>
<td>77</td>
<td>75</td>
<td>PI-103</td>
<td>5.78</td>
</tr>
<tr>
<td>PIK3CA/PIK3R3 (p110 alpha/p55 gamma)</td>
<td>PIP2:PS</td>
<td>166</td>
<td>150</td>
<td>PI-103</td>
<td>14.0</td>
</tr>
<tr>
<td>PIK3CB/PIK3R1 (p110 beta/p85 alpha)</td>
<td>PIP2:PS</td>
<td>171</td>
<td>150</td>
<td>PI-103</td>
<td>19.5</td>
</tr>
<tr>
<td>PIK3CD/PIK3R1 (p110 delta/p85 alpha)</td>
<td>PIP2:PS</td>
<td>63</td>
<td>75</td>
<td>PI-103</td>
<td>6.30</td>
</tr>
<tr>
<td>PIK3CG (p110 gamma)</td>
<td>PIP2:PS</td>
<td>31</td>
<td>25</td>
<td>PI-103</td>
<td>32.2</td>
</tr>
<tr>
<td>PIP4K2A</td>
<td>P(5)P</td>
<td>1</td>
<td>N/A</td>
<td>Staurosporine</td>
<td>21000</td>
</tr>
<tr>
<td>PIP5K1A/PIK3R1 (p110 delta/p85 alpha)</td>
<td>P(3;4)P2</td>
<td>10.3</td>
<td>10</td>
<td>JAK3 Inhibitor V</td>
<td>6790</td>
</tr>
<tr>
<td>Sphingosine Lipid Substrate</td>
<td>214</td>
<td>N/A</td>
<td>JAK3 Inhibitor V</td>
<td>1430</td>
<td>*</td>
</tr>
</tbody>
</table>